By Chris Wack

Sientra Inc. said the U.S. Food and Drug Administration approved the Low Plus Profile Projection Breast Implant for breast augmentation in women at least 22 years old, and for women of all ages undergoing breast reconstruction.

The company said the product will be commercially available for board-certified and board-eligible plastic surgeons in the U.S. in late July.

Sientra shares were up 13% to 99 cents in premarket trading.

Write to Chris Wack at chris.wack@wsj.com

(END) Dow Jones Newswires

July 06, 2022 09:29 ET (13:29 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.
Sientra (NASDAQ:SIEN)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Sientra Charts.
Sientra (NASDAQ:SIEN)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Sientra Charts.